LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Brazil Green Lights VEXIM’s SpineJack
Spine

Brazil Green Lights VEXIM’s SpineJack

June 9, 2017 2 min read Premium comments

Advertisement

Brazil Green Lights VEXIM’s SpineJack
SpineJack / Courtesy: Vexim
Secondary

VEXIM, a medical device company based in Toulouse, France, has just received the green light to commercialize SpineJack in Brazil. Approval came from ANVISA, Brazil’s National Health Surveillance Agency.

SpineJack is indicated for reduction of spinal fractures resulting from osteoporosis, trauma fractures, malignant lesions myeloma or osteolitic metastasis. It is intended to be used in combination with validated bone cement, and to be placed, using a transpedicular approach, through a vertebra pedicle with a minimum internal diameter, as verified with a pre-operative CT scan.

“The approval from ANVISA is a key achievement opening a new opportunity for VEXIM in this important international market with untapped potential,” says the May 29th, 2017 news release. “This clearance will provide us with new growth opportunities in this key Latin American market. VEXIM estimates that Brazil alone today represents a €15 million market in the vertebral compression fractures field.”

“This approval will enable us to have substantial growth in our international business. The company is expecting to initiate export to Brazil in the coming months, after the conclusion of the product’s evaluation process and of distribution partnerships”, said Vincent Gardès, CEO of VEXIM.

Gardès told OTW, “As part of our international expansion strategy we have selected countries with high market potentials. Brazil is considered as a sizable market opportunity for Vexim with its 15M€ market. We also believe this market will grow substantially in the upcoming decades based on economy development, aged population and better access to medical treatments.”

“We initiated our regulatory process for Brazil in 2010. The ANVISA process is made of multiple steps and control procedures that are required to register medical devices. We received a GMP (good manufacturing process) approval already in 2015 that a first good signal for our regulatory process.”

“From a Brazilian standpoint, we are thrilled to bring our SpineJack product and concept to the country and we strongly believe this will be a game changer in the way we treat vertebral fractures going forward. We have been experiencing success in Latin America for several years but Brazil is definitely the most important opportunity there. To the orthopedic surgeon community around the world, we would like to reaffirm our commitment and dedication to bring them world-class innovation when dealing with spine trauma diseases where ever those surgeons are working.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy